首页> 外文期刊>EFSA supporting publications >Response to comments on the Scientific Opinion of the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) on the scientific substantiation of a health claim related to Bifidobacterium animalis subsp. lactis Bi-07 contributes to increasing lactose digestion pursuant to Article 13.5 of Regulation (EC) No 1924/2006
【24h】

Response to comments on the Scientific Opinion of the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) on the scientific substantiation of a health claim related to Bifidobacterium animalis subsp. lactis Bi-07 contributes to increasing lactose digestion pursuant to Article 13.5 of Regulation (EC) No 1924/2006

机译:响应关于营养,新型食品和食品过敏原(NDA)对与双歧杆菌患者有关的健康索赔的科学证实的科学意见的评论。 乳酸BI-07根据第1924/2006条的第13.5条增加,增加乳糖消化

获取原文
           

摘要

Following a request from the European Commission, EFSA was asked to review the scientific comments received on the Scientific Opinion of the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) on the scientific substantiation of a health claim related to Bifidobacterium animalis subsp. lactis Bi-07 contributes to increasing lactose digestion pursuant to Article 13.5 of Regulation (EC) No 1924/2006. Comments originating from the applicant (DuPont) were submitted to EFSA via the European Commission Services. EFSA has reviewed the comments with the contribution of the chair of the NDA Working Group on Claims, the chair of the NDA Panel and the Working Group on Claims of the NDA Panel. In its opinion adopted on 1July 2020 the EFSA Panel on Nutrition, Novel Foods andFood Allergens (NDA) concluded that a cause and effect relationship has not been established between the consumption ofBifidobacterium animalis subsp. lactis Bi-07 and a beneficial physiological effect (i.e. the improvement of symptoms of lactose maldigestion) in individuals with lactose maldigestion. The comments received do not require any change in the conclusions of the NDA Panel.
机译:遵循欧盟委员会的请求后,EFSA被要求审查关于营养,新型食品和食品过敏原(NDA)的科学意见的科学意见,并科学证实与双歧双歧杆菌患者有关的健康索赔。乳酸BI-07根据第1924/2006条的第13.5条增加,增加乳糖消化。来自申请人(DuPont)的评论通过欧洲委员会服务提交给EFSA。 EFSA已审查了索赔主席申请主席,索赔,纳达小组主席和“债券小组索赔的工作组”的贡献。在2020年220年通过的意见中,EFSA营养小组,新型食物和食品过敏原(NDA)的结论是,植物消费患者之间尚未确定原因和效应关系。 Lactis Bi-07和有益的生理效果(即乳糖混合物症状的改善)在乳糖混合物中的个体中的个体。收到的评论不需要任何改变NDA小组的结论。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号